248 related articles for article (PubMed ID: 21415363)
1. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity.
Wender PA; Baryza JL; Brenner SE; DeChristopher BA; Loy BA; Schrier AJ; Verma VA
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6721-6. PubMed ID: 21415363
[TBL] [Abstract][Full Text] [Related]
2. Function through synthesis-informed design.
Wender PA; Quiroz RV; Stevens MC
Acc Chem Res; 2015 Mar; 48(3):752-60. PubMed ID: 25742599
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.
Abdelnabi R; Staveness D; Near KE; Wender PA; Delang L; Neyts J; Leyssen P
Biochem Pharmacol; 2016 Nov; 120():15-21. PubMed ID: 27664855
[TBL] [Abstract][Full Text] [Related]
4. The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.
Wender PA; Verma VA
Org Lett; 2008 Aug; 10(15):3331-4. PubMed ID: 18588309
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
Raghuvanshi R; Bharate SB
Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
[TBL] [Abstract][Full Text] [Related]
6. Deletion of the C26 Methyl Substituent from the Bryostatin Analogue Merle 23 Has Negligible Impact on Its Biological Profile and Potency.
Zhao X; Kedei N; Michalowski A; Lewin NE; Keck GE; Blumberg PM
Chembiochem; 2018 May; 19(10):1049-1059. PubMed ID: 29517836
[TBL] [Abstract][Full Text] [Related]
7. Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation.
Abramson E; Hardman C; Shimizu AJ; Hwang S; Hester LD; Snyder SH; Wender PA; Kim PM; Kornberg MD
Cell Chem Biol; 2021 Apr; 28(4):537-545.e4. PubMed ID: 33472023
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.
Irie K; Yanagita RC
Chem Rec; 2014 Apr; 14(2):251-67. PubMed ID: 24677503
[TBL] [Abstract][Full Text] [Related]
9. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
Kedei N; Lewin NE; Géczy T; Selezneva J; Braun DC; Chen J; Herrmann MA; Heldman MR; Lim L; Mannan P; Garfield SH; Poudel YB; Cummins TJ; Rudra A; Blumberg PM; Keck GE
ACS Chem Biol; 2013 Apr; 8(4):767-77. PubMed ID: 23369356
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.
Hardman C; Ho S; Shimizu A; Luu-Nguyen Q; Sloane JL; Soliman MSA; Marsden MD; Zack JA; Wender PA
Nat Commun; 2020 Apr; 11(1):1879. PubMed ID: 32312992
[TBL] [Abstract][Full Text] [Related]
11. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog.
Wender PA; Baryza JL; Brenner SE; Clarke MO; Craske ML; Horan JC; Meyer T
Curr Drug Discov Technol; 2004 Jan; 1(1):1-11. PubMed ID: 16472215
[TBL] [Abstract][Full Text] [Related]
12. Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.
Wender PA; Nakagawa Y; Near KE; Staveness D
Org Lett; 2014 Oct; 16(19):5136-9. PubMed ID: 25238583
[TBL] [Abstract][Full Text] [Related]
13. Function-Oriented Synthesis: Design, Synthesis, and Evaluation of Highly Simplified Bryostatin Analogues.
Wender PA; Sloane JL; Luu-Nguyen QH; Ogawa Y; Shimizu AJ; Ryckbosch SM; Tyler JH; Hardman C
J Org Chem; 2020 Dec; 85(23):15116-15128. PubMed ID: 33200928
[TBL] [Abstract][Full Text] [Related]
14. Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.
Loy BA; Lesser AB; Staveness D; Billingsley KL; Cegelski L; Wender PA
J Am Chem Soc; 2015 Mar; 137(10):3678-85. PubMed ID: 25710634
[TBL] [Abstract][Full Text] [Related]
15. Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes.
Kazanietz MG; Lewin NE; Gao F; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Aug; 46(2):374-9. PubMed ID: 8078499
[TBL] [Abstract][Full Text] [Related]
16. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
Ruan BF; Zhu HL
Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
[TBL] [Abstract][Full Text] [Related]
17. Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity.
Keck GE; Poudel YB; Rudra A; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Bioorg Med Chem Lett; 2012 Jun; 22(12):4084-8. PubMed ID: 22579485
[TBL] [Abstract][Full Text] [Related]
18. Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.
Wender PA; Staveness D
Org Lett; 2014 Oct; 16(19):5140-3. PubMed ID: 25238640
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core.
Kraft MB; Poudel YB; Kedei N; Lewin NE; Peach ML; Blumberg PM; Keck GE
J Am Chem Soc; 2014 Sep; 136(38):13202-8. PubMed ID: 25207434
[TBL] [Abstract][Full Text] [Related]
20. "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo.
DeChristopher BA; Fan AC; Felsher DW; Wender PA
Oncotarget; 2012 Jan; 3(1):58-66. PubMed ID: 22308267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
